Plasma‐derived C1 esterase inhibitor vs placebo or active control
Serious adverse events (during · children or adults with Types I or II HAE
It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
1 finding from 1 review
- Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes onlyRR 0.54 [0.09, 3.1]1 study · 71 participantsVery low